The DOI matches its Crossref record.
Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer
Abstract
Triple-negative breast cancer (TNBC) lacks three important receptors, ER, PR, and HER2. It is more aggressive and more likely to relapse after treatment, thus has been identified as one of the most malignant breast cancer types. The development of efficient targeted TNBC therapy is an important research topic in TNBC treatment. We report the development of a new aptamer-drug conjugate (ApDC), AS1411-triptolide conjugate (ATC), as targeted therapy for the treatment of TNBC with high efficacy. The conjugate possesses excellent specificity and high cytotoxicity against the MDA-MB-231 cell line. The advantages of our newly invented ATC are further highlighted by its excellent in vivo anti-TNBC efficacy and negligible side effects toward healthy organs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Triptolide has been shown to inhibit various types of tumors [258–260], by regulating cell growth, apoptosis, autophagocytosis, and angiogenesis [261].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [260]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 35
- 10.1056/NEJMra1001389 · DOI
- 10.1158/1078-0432.CCR-06-3045 · DOI · Paper page
- 10.1038/nrclinonc.2016.66 · DOI · Paper page
- 10.1016/j.ctrv.2009.12.002 · DOI
- 10.1016/j.ctrv.2017.11.003 · DOI
- 10.1016/S0889-857X(05)70118-6 · DOI
- 10.1016/j.phytochem.2007.03.016 · DOI
- 10.3109/10428190109064582 · DOI
- 10.1002/jat.2906 · DOI
- 10.1126/scitranslmed.3004334 · DOI
- 10.1002/anie.201606121 · DOI
- 10.1002/anie.201408817 · DOI
- 10.3109/1061186X.2013.856011 · DOI
- 10.1038/nrd3141 · DOI · Paper page
- 10.1038/nrd.2016.199 · DOI
- 10.1002/cbic.200800805 · DOI
- 10.1021/ja4117395 · DOI
- 10.1002/anie.201903807 · DOI
- 10.1038/am.2015.19 · DOI
- 10.1073/pnas.1220817110 · DOI
- 10.1038/s41467-017-01565-6 · DOI
- 10.1002/anie.201812650 · DOI
- 10.1002/anie.200602251 · DOI
- 10.1084/jem.20120950 · DOI
- 10.1016/j.biomaterials.2015.08.007 · DOI
- 10.1007/s10637-013-0045-6 · DOI
- 10.1021/nn901374b · DOI
- 10.1021/ja5079464 · DOI
- 10.1038/leu.2017.215 · DOI
- 10.1021/acs.nanolett.8b02732 · DOI
- 10.1007/s12282-013-0496-9 · DOI
- 10.1046/j.1432-1033.2003.03929.x · DOI
- 10.2147/IJWH.S44074 · DOI
- 10.1016/j.yexmp.2009.01.004 · DOI · Paper page
- 10.1038/aps.2014.162 · DOI
Cited by
Sorted by citations
Emerging role of exosomes in cancer therapy: progress and challenges
Li, J., Wang, J., & Chen, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02215-4 · Cited by 297
Metadata
- Authors
- He, J., Peng, T., Peng, Y., Ai, L., Deng, Z., Wang, X.-Q., & Tan, W.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-01-07
- Volume
- 142
- Issue
- 6
- Pages
- 2699-2703
- ISSN
- 0002-7863
- 1520-5126
- Cited by
- 160
- References
- 0
- Language
- en
- Licence
- Funders
- National Natural Science Foundation of China (21804037, 21827811, 61527806)
- Science and Technology Project of Hunan Province (2017XK2103)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer. https://app.cochat.ai/papers/10.1021/jacs.9b10510
- The paper
- He, J., Peng, T., Peng, Y., Ai, L., Deng, Z., Wang, X.-Q., & Tan, W. (2020). Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.9b10510